

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number
WO 03/000056 A1

(51) International Patent Classification⁷: **A01N 43/04**

(21) International Application Number: PCT/US02/20703

(22) International Filing Date: 25 June 2002 (25.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/300,942 25 June 2001 (25.06.2001) US

(71) Applicant (*for all designated States except US*): **INSPIRE PHARMACEUTICALS, INC.** [US/US]; Suite 470, 4222 Emperor Blvd., Durham, NC 27703 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **COWLEN, Matthew, S.** [US/US]; 208 Clark Lake Road, Chapel Hill, NC 27707 (US). **YERXA, Benjamin, R.** [US/US]; 3119 Birnamwood Road, Raleigh, NC 27607 (US). **JONES, Arthur, C.** [US/US]; 5 Winnabow Court, Durham, NC 27703 (US). **BROWN, Edward, G.** [US/US]; 302 Glenmore Road, Apex, NC 27502 (US).

(74) Agents: **HALLUIN, Albert, P.** et al.; Howrey Simon Arnold & White LLP, 301 Ravenswood Avenue, Menlo Park, CA 94025 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: JOINT LUBRICATION WITH P2Y PURINERGIC RECEPTOR AGONISTS

(57) **Abstract:** The present invention is directed to a method of altering the amount or composition of synovial fluids secreted from joints in a subject in need of such treatment. The method comprises administering to a subject a pharmaceutical composition comprising a P2Y purinergic receptor agonist in an amount effective to alter the amount or composition of synovial fluids. The P2Y purinergic receptor agonist is administered in an amount effective to stimulate secretion of synovial fluid, lubricin, hyaluronic acid, or surface-active phospholipids; to enhance joint lubrication; or to treat osteoarthritis. The pharmaceutical compositions useful in the present invention comprise a P2Y purinergic receptor agonist of Formula I and include, but are not limited to: uridine-, adenosine-, cytidine-5'-di- or triphosphates, dinucleoside polyphosphates, and analogs thereof. The invention is useful for treating conditions associated with reduced joint lubrication and joint stiffness, such as osteoarthritis.



WO 03/000056 A1

JOINT LUBRICATION WITH P2Y PURINERGIC RECEPTOR AGONISTS

TECHNICAL FIELD

5 This invention relates to a method of stimulating the secretion of synovial fluid, mucins, hyaluronic acid, and/or surface-active phospholipids, and thereby enhancing joint lubrication, using P2Y purinergic receptor agonists in patients in need of such treatment.

BACKGROUND OF THE INVENTION

10 The joint cavity is surrounded by a capsule and held together by ligaments. Synovium lines the joint cavity and is folded upon itself several times to permit considerable motion. The inner portion of the synovium is lined with a layer of synoviocytes, consisting of Type A cells which are involved in phagocytosis and secretion, and Type B cells which are believed to synthesize the hyaluronate of synovial
15 fluid (Bora, *et al.*, *Hand Clin.* 3: 325-336 (1987)).

 Human joints are lubricated by fluid secreted from synovial membranes, which line internal, non-articular joint surfaces. The lubricating properties of synovial fluid have been attributed to a surfactant consisting of surface-active phospholipid (SAPL), the mucinous glycoprotein lubricin, hyaluronic acid (hyaluronan), and water (Schwarz, *et al.*,
20 *Br. J. Rheumatol.* 35: 821-827 (1996), Jay, *et al.*, *J. Rheumatol.* 27: 594-600 (2000), Marshall, *et al.*, *Curr. Opin. Rheumatol.* 12: 468-474 (2000), Bora, *et al.*, *Hand Clin.* 3: 325-336 (1987), Hills, *et al.*, *Br. J. Rheumatol.* 37: 143-147 (1998), Jay, *et al.*, *Connect. Tissue Res.* 28: 245-255 (1992), Hills, *et al.*, *Proc. Inst. Mech. Eng.* 214: 83-94 (2000)). Hyaluronan is a critical constituent component of normal synovial fluid and an important
25 contributor to joint homeostasis. Hyaluronan imparts anti-inflammatory and antinociceptive properties to normal synovial fluid and contributes to joint lubrication, buffering load transmission across articular surfaces and providing a continually replenished source of hyaluronan to articular tissues. (Marshall, *Curr. Opin. Rheumatol.* 12: 468-474 (2000)).

30 Joint lubrication is compromised in osteoarthritis (OA) ((Schwarz, *et al.*, *Br. J. Rheumatol.* 35: 821-827 (1996), Marshall, *et al.*, *Curr. Opin. Rheumatol.* 12: 468-474 (2000), Hills, *et al.*, *Br. J. Rheumatol.* 37: 143-147 (1998), Hills, *et al.*, *Proc. Inst. Mech. Eng.* 214: 83-94 (2000)) and following arthroplastic surgery (Delecrin, *et al.*, *Clin. Orthop.* 307: 240-249 (1994)). OA is a degenerative joint disease characterized by

progressive deterioration and loss of articular cartilage associated with proliferation of new bone and soft tissue in and around the joint. OA can be classified as: (1) primary, in which no underlying cause is apparent; (2) secondary, which is associated with a predisposing factor such as trauma, repetitive stress (occupation, sports), congenital abnormality, metabolic disorder, or other bone/joint disease; and (3) erosive, characterized by hand OA associated with synovitis and radiographic central erosions of the articular surface. Unlike rheumatoid arthritis, a systemic disease simultaneously affecting multiple joints, OA involves only joints that are traumatized or exposed to mechanical abuse. OA develops essentially when the rate of wear exceeds the production of new collagen fibers by chondrocytes. The lipids within the joint, including phospholipid, change in profile shortly after an impact injury leading to eventual OA, whether bone fracture occurs or not (Rabinowitz, *et al.*, *Clinical Orthopedics and Related Res.* 190: 292-298 (1984)). The following symptoms and criteria are used to establish a diagnosis of osteoarthritis:

Patient History:

Typical symptoms of osteoarthritis include use-related pain affecting one or a few joints with less common rest and nocturnal pain, and brief stiffness after rest or in the morning, lasting less than 30 minutes. Other symptoms include loss of joint movement or functional limitation joint instability, deformity and crepitation ('crackling').

Physical Examination:

Physical examination reveals chronic monarthrititis or asymmetric oligo/polyarthrititis and firm or "bony" swellings of the joint margins, such as Heberden's or Bouchard's nodes. Patients rarely display synovitis with a cool effusion. On physical examination, crepitation, an audible creaking or crackling of the joints on movement is sometimes detected. Osteoarthritis is also associated with deformity. Patients display restriction of movement, such as the limitation of internal rotation of the hip. Objective neurologic abnormalities are sometimes observed when the spine is involved and affect intervertebral disks, apophyseal joints and paraspinal ligaments.

Laboratory Studies:

Routine laboratory work is normal and conducted to rule out other causes of arthritis such gout, and to detect other primary disorders. Erythrocyte sedimentation rate is normal but is sometimes elevated in patients with synovitis.

Joint Fluid Analysis:

Analysis of the joint fluid provides information about the joint fluid characteristics of osteoarthritis. The joint fluid is normally straw-colored with good viscosity and the number of joint fluid white blood cells (WBC) less than 2000/ μ L. Analysis of the joint fluid is important in ruling out crystal-induced arthritis or infection.

X-ray Findings:

As the disease progresses and over a long-term duration, radiographic findings include joint space narrowing, subchondral bone sclerosis, subchondral cysts, and osteophytes. Erosions differ from that characteristic of rheumatoid and psoriatic arthritis because they occur subchondrally along the central portion of the joint surface.

When SAPL is injected into osteoarthritic joints, wear associated with OA is successfully reduced (Hills, *Proc. Inst. Mech. Eng.* 214: 83-94 (2000)). In OA, the concentration and molecular weight of hyaluronan in synovial fluid is reduced by dilution, fragmentation, and production by synoviocytes of hyaluronan of lower than normal molecular weight. Consequently, the homeostatic condition of synovial fluid maintained by hyaluronan is compromised (Marshall, *Curr. Opin. Rheumatol.* 12: 468-474 (2000)). The outermost lubricating layer of SAPL deposited onto articular cartilage from synovial fluid is deficient in OA (Hills and Monds, *Br. J. Rheumatol.* 37: 143-147 (1998)). Studies of changes in joint fluid after total arthroplasty in a rabbit model of total knee replacement have shown that joint fluid volume and total protein concentration recovers to normal, but hyaluronic acid concentration and molecular weight are reduced and do not completely recover to normal values (Delecrin, *et al., Clinical Orthopaedics and Related Research* 307: 240-249 (1994)).

The recognition that synovial fluid hyaluronan in OA is abnormal led to the proposition that removal of pathologic osteoarthritic synovial fluid and replacement with products that restore the molecular weight and concentration of hyaluronan toward normal levels can have a beneficial therapeutic effect. The treatment approach has been termed viscosupplementation (Marshall, *Curr. Opin. Rheumatol.* 12: 468-474 (2000)). Commercial preparations of hyaluronic acid (Healon), which has joint lubricating qualities, have been used as a viscosupplementation treatment for OA (Jay, *et al., J. Biomed. Matl. Res.* 40: 414-418 (1998)). However, commercial preparations of hyaluronic acid possess inferior lubricating qualities compared with synovial mucin (Jay, *et al., J. Biomed. Matl. Res.* 40: 414-418 (1998)). Pharmacotherapeutic agents used to manage arthritis include analgesics, anti-inflammatory drugs, muscle relaxants, and

antidepressants. Aspirin is the drug of choice for both anti-inflammatory and analgesic reasons. Other non-steroidal anti-inflammatory drugs may be used and act by inhibiting lipo-oxygenase conversion of cell membrane lipids to arachidonic acid. Topical capsaicin cream may help to relieve hand or knee pain and acts by causing the release of the peptide substance P from sensory neurons. Muscle relaxants are used usually in low doses and include diazepam, cyclobenzaprine, carisoprodol, and methocarbamol. Although corticosteroids are not administered orally, they can be administered intra-articularly to reduce inflammation and on an intermittent basis to avoid acceleration of cartilage breakdown. However, the crystalline preparations of corticosteroids may cause synovitis. Purely analgesic agents and tricyclic antidepressants for depression may also be useful. However, nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and indomethacin, and newer NSAIDs with specificity for cyclooxygenase-2 (COX-2 inhibitors), including celecoxib, are known to induce gastrointestinal toxicity (Mundasad, *et al.*, *J. Ocul. Pharmacol. Ther.*, 17(2): 173-179 (2001)).

As described above, pharmacotherapeutic agents commonly used to treat OA may cause adverse side effects, such as the gastrointestinal toxicity, and do not directly improve joint fluid properties or enhance joint lubrication. There exists a need for agents that are both safe and effective in treating OA by enhancing joint lubrication.

P2Y receptor agonists are known to induce the secretion of mucins, surfactant, and water from respiratory epithelial surfaces in the lung (Yerxa and Johnson, *Drugs Future* 24: 759-769 (1999); Benali, *et al.*, *Am. J. Respir. Cell. Mol. Biol.* 10: 363-368 (1994); Gobran, *et al.*, *Am. J. Physiol.* 267: L625-L633 (1994); Knowles, *et al.*, *New Engl. J. Med.* 325: 533-538 (1991); Lethem, *et al.*, *Am. J. Respir. Cell. Mol. Biol.* 9: 315-322 (1993)). In addition, P2Y receptor agonists induce tear fluid secretion and improve the lubrication and hydration of the ocular surface in dry eye disease by stimulating the release of mucins and water from the conjunctival epithelium (Hosoya, *et al.*, *J. Pharmacol. Exp. Ther.* 291 (1): 53-59 (1999); Murakami, *et al.*, *Invest. Ophthalmol. Vis. Sci.* 41(4): S457 (ARVO Abstract 2423 (2000); Murakami, *et al.*, *Curr. Eye Res.* 21(4): 782-787 (2000); Shiue, *et al.*, *Life Sci.* 66(7): PL105-111 (2000); Jumblatt and Jumblatt, *Exp. Eye Res.* 67: 341-346 (1998)). However, P2Y receptors are not known to have any beneficial affect on the joint or in joint lubrication.

It is also known that P2Y receptor agonists modulate all components of the mucociliary clearance (MCC) system by: (1) increasing both the rate and total amount of mucin secretion by goblet cells *in vitro* (Lethem, *et al.*, *Am. J. Respir. Cell. Mol. Biol.* 9:

315-22 (1993)); (2) increasing cilia beat frequency in human airway epithelial cells *in vitro* (Drutz, *et al.*, *Drug Dev. Res.* 37(3): 185 (1996)); (3) increasing Cl⁻ secretion, hence, water secretion from airway epithelial cells *in vitro* (Mason, *et al.*, *Br. J. Pharmacol.* 103: 1649-1656 (1991); and (4) releasing surfactant from Type II alveolar cells (Gobran, *Am. J. Physiol.* 267: L625-L633 (1994)). In addition to such actions, P2Y agonists have also been shown to increase intracellular Ca⁺⁺ due to stimulation of phospholipase C by the P2Y₂ receptor (Brown, *et al.*, *Mol. Pharmacol.* 40: 648-655 (1991); Yerxa and Johnson, *Drugs of the Future* 24(7): 759-769 (1999)). U.S. Patent Nos. 5,789,391; 5,763,447; 5,635,160; 5,935,555; 5,656,256; 5,628,984; 5,902,567; 5,292,498; 5,837,861; 5,900,407; 5,972,904; 5,981,506; 5,958,897; 5,968,913; 6,022,527; 6,133,247; and 6,143,279, and PCT International Patents WO97/29756, WO97/35591, WO96/40059, WO97/05195, WO94/08593, WO98/19685, WO98/15835, WO98/03182, WO98/03177, WO98/34942, WO98/34593, WO99/09998, WO99/32085, WO99/61012, WO 00/30629, WO 00/50024, and WO96/40059 disclose beneficial therapeutic effects of dinucleotides and related compounds in sinusitis, otitis media, ciliary dyskinesia, pneumonia associated with immobilization, lung disease, cystic fibrosis, dry eye disease, vaginal dryness, bronchitis, edematous retinal disorders, retinal degeneration and detachment, and gastrointestinal disease.

20

SUMMARY OF THE INVENTION

The present invention is directed to a method of altering the amount or composition of synovial fluids secreted from joints in a subject in need of such treatment. The method comprises administering to a subject a pharmaceutical composition comprising a P2Y purinergic receptor agonist in an amount effective to alter the amount or composition of synovial fluids. The P2Y purinergic receptor agonist is administered in an amount effective to stimulate secretion of synovial fluid, lubricin, hyaluronic acid, or surface-active phospholipids; to enhance joint lubrication, or to treat osteoarthritis. The pharmaceutical compositions useful in the present invention comprise a P2Y purinergic receptor agonist or combination of agonist together with a pharmaceutically acceptable carrier therefor. P2Y purinergic receptor agonists are compounds of Formula I and include, but are not limited to: uridine-, adenosine-, cytidine-5'-di- or triphosphates, dinucleoside polyphosphates, and analogs thereof.

30

Routes of administration of the pharmaceutical composition include, but are not limited to: topical administration via liquid, cream, gel, ointment, foam, pessary, or tablet;

systemic administration via nasal drops or spray, inhalation (nebulizer or other device), oral form (liquid or pill), injectable form, suppository form, or transdermal form; and intra-articular administration by direct injection into the joint cavity. Systemic administration and intra-articular administration can also be accomplished via sustained
5 release, such as by an implanted device.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the effects of UTP, ATP and 2-methylthio ADP on cytosolic calcium levels in synoviocytes.

10

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method of altering the amount or composition of synovial fluids secreted from joints in a subject in need of such treatment. Components that determine the lubricating properties of synovial fluid and can be altered by systemic
15 or local treatment with purinergic receptor agonists include water, mucinous glycoprotein lubricin, hyaluronic acid, and/or surface-active phospholipids. Increasing the amount of, or changing the component ratio in synovial fluids can enhance lubrication in joints, and improve disorders associated with reduced joint secretion and lubrication, such as osteoarthritis and complications of knee and hip replacement. Thus, an embodiment of
20 the present invention is to enhance the secretion of synovial fluid, lubricin, hyaluronic acid, and/or surface-active phospholipids. The method comprises administering to a subject in need thereof a formulation comprising a purinergic receptor agonist or a combination of purinergic receptor agonists in an amount effective to alter the amount or composition of synovial fluids from joints such as knee, hip and shoulder. The P2Y
25 purinergic receptor agonist stimulates P2Y purinergic receptors, which causes the interaction of signaling pathways leading to prosecretory effects.

Another embodiment of the present invention is a method of increasing lubrication in joints by administering a purinergic receptor agonist. Such method provides for the prevention, management and/or treatment of deficiencies of joint
30 secretion and/or lubrication arising from, but not limited to, arthritis, osteoarthritis, joint surgery, knee and hip replacement, and arthroplastic surgery (joint replacement) in mammals, preferably humans.

The methods of the present invention can be used exclusive of, or as an adjunct to, anti-inflammatory and analgesic agents commonly used to treat disorders associated with


joint stiffness, such as arthritis. A combined therapeutic approach is beneficial in reducing side effects associated with agents, such as non-steroidal, anti-inflammatory drugs (NSAIDs), commonly used to prevent, manage, or treat disorders such as OA associated with reduced joint lubrication. In addition to enhancing safety, a combined
 5 therapeutic approach is also advantageous in increasing efficacy of treatment.

DESCRIPTION OF COMPOUNDS

P2Y agonists include nucleoside polyphosphates or dinucleoside polyphosphates of general Formula I. Nucleoside triphosphates useful in this application include uridine-
 10 5'-triphosphate (UTP), adenosine-5'-triphosphate (ATP), cytidine-5'-triphosphate (CTP) and their analogues of general Formula I; dinucleoside polyphosphates of general Formula I are also useful in this application.

Disclosed are compounds of Formula I:

Formula I



wherein:

X_1 , X_2 , and X_3 are independently or together oxygen, methylene, monochloromethylene,
 20 dichloromethylene, monofluoromethylene, difluoromethylene, or imido;

T' , T , W , and V are independently or together oxygen or sulfur;

$m = 0, 1$ or 2 ;

$n = 0$ or 1 ;


$p = 0, 1$, or 2 ;

25 where the sum of $m+n+p$ is from 1 to 5;

each M is independently hydrogen or a pharmaceutically-acceptable inorganic or organic counterion;

$A = M$, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aralkenyl, aralkynyl, aryl, or acylthioalkyl, with or without substituents or heteroatoms; or

A is a nucleoside residue which is defined as:



5 wherein:

D_1 and D_2 are each independently O or C.


Z and Z' are independently H, OR_2 or OR_3 ;

Y and Y' are independently H, F, OR_1 or OR_4 ;

independently R_1 , R_2 , R_3 , and R_4 is H, or a residue according to Formula II, provided that

10 at least one R_1 , R_2 , R_3 , or R_4 is H;

Formula II



15 wherein:

Q is a carbon atom;

R_5 , R_6 , and R_7 are independently H, alkyl, cycloalkyl, aralkyl, aryl, substituted aralkyl, substituted aryl, or heterocyclic moiety, or R_5 and R_6 are taken together to form a carbocyclic or heterocyclic ring of 4 to 7 members, such that the moiety defined

20 according to Formula II is an ether; or

provided that R_5 and R_6 are taken together as oxygen or sulfur doubly bonded to Q, and R_7 is alkyl, cycloalkyl, aralkyl, substituted aralkyl, aryl, substituted aryl, or a heterocycle of 4 to 7 members, such that the moiety defined according to Formula II is an ester or thioester; or


25 provided that R_5 and R_6 are taken together as oxygen or sulfur doubly bonded to Q, and R_7 is amino or mono- or disubstituted amino, where the substituents are alkyl, cycloalkyl, aralkyl, aryl, substituted aralkyl, or substituted aryl, or where the substituents on nitrogen form a heterocyclic ring of 4 to 7 members such that the moiety according to Formula II is a carbamate or thiocarbamate; or

provided that R₅ and R₆ are taken together as oxygen or sulfur doubly bonded to Q, and R₇ is alkoxy, cycloalkoxy, aralkyloxy, aryloxy, substituted aralkyloxy, or substituted aryloxy, such that the moiety according to Formula II is a carbonate or thiocarbonate;

B and B' are independently a purine or a pyrimidine residue according to


- 5 Formulae III or IV which is linked to the 1'-position of the furanose or carbocycle via the 9-position of the purine or the 1-position of the pyrimidine.

Formula III



10

Formula IV




15

wherein:

R₁₀ and R₁₄ are independently CN, N₃, hydroxy, oxo, amino, mercapto, alkylthio, alkoxy, aryloxy, alkylamino, cycloalkylamino, aralkylamino, arylamino, diaralkylamino, diarylamino, N-alkyl-N-arylamino, or dialkylamino, where the alkyl and/or aryl groups are optionally linked to form a heterocycle; or

- 5 R₁₀ and R₁₄ are independently acylamino, according to Formula V;

Formula V



10

or, when R₁₀ or R₁₄ has as its first atom nitrogen, R₁₀ and R₁₁ or R₁₄ and R₁₅ are optionally taken together as -CH=CH- to form a 5-membered, fused imidazole ring (an etheno compound), optionally substituted on the imidazole ring of the etheno-compound with substituted- or unsubstituted- alkyl, cycloalkyl, aralkyl, or aryl moieties;

15

J is carbon or nitrogen, with the provision that when J is nitrogen, R₁₂ is not present;

R₁₁ is hydrogen, O (adenine 1-oxide derivatives) or is absent (adenine derivatives);

R₁₂, when present, is hydrogen, alkyl, azido, amino, alkylamino, arylamino, aralkylamino, dialkylamino, diarylamino, diaralkylamino, N-alkyl-N-arylamino, N-alkyl-N-

20

aralkylamino, N-aralkyl-N-arylamino, hydroxy, alkoxy, aryloxy or aralkyloxy,

sulfhydryl, alkylthio, arylthio or aralkylthio, or ω-X(C₁₋₆alkyl)G-, wherein X is substituted- or unsubstituted- amino, mercapto, hydroxy or carboxyl, and G is chosen from -O- (to give an ether), -S- (to give a thioether), -NR₂₀- (to give an amine), -N(CO)R₂₀- (to give an amide), or N(CO)OR₂₂ (to give a carbamate);

25

R₁₃ is hydrogen, chlorine, fluorine, hydroxy, alkoxy, aryloxy, aralkyloxy, amino, monosubstituted amino, disubstituted amino, alkylthio, trifluoroalkylthio, arylthio, or aralkylthio, where the substituent on sulfur contains up to a maximum of 20 carbon atoms, with or without unsaturation;

R₁₅ is hydrogen, or acyl (e.g. acetyl, benzoyl, phenylacetyl, with or without substituents);

R₁₆ is hydrogen, methyl, substituted- or unsubstituted-alkyl, halo, aryl, aralkyl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl;

R₁₇ is halogen, hydrogen, alkoxy or is an acylamino group according to Formula V; or

R₁₆ and R₁₇, when taken together, represent a ring of 5 to 7 members, with or without
5 heteroatoms or substituents;

R₁₈ is hydrogen, oxo, alkoxy, amino, alkylamino, arylamino, aralkylamino, dialkylamino, diarylamino, arylalkylamino, arylaralkylamino, alkylaralkylamino, sulfhydryl, alkylthio, arylthio, aralkylthio, or acylamino according to Formula V;

R₁₉ is amino or mono- or disubstituted amino such that the moiety according to Formula
10 V is a urea or thiourea; or

R₁₉ is alkoxy, aralkyloxy or aryloxy, such that the moiety according to Formula V is a carbamate or thiocarbamate; or

R₁₉ is hydrogen, alkyl, cycloalkyl, aralkyl, or aryl, with or without substituents or heteroatoms, such that the moiety according to Formula V is an amide or thioamide;

15 R₂₀ and R₂₁ independently are hydrogen, alkyl, cycloalkyl, aralkyl, or aryl, with or without substituents or heteroatoms;

R₂₂ is alkyl, cycloalkyl, aralkyl, or aryl, with or without substituents or heteroatoms; and

W₁ is oxygen or sulfur.

When D₁ and D₂ are oxygen, the furanosyl moieties of Formula I independently
20 can be in the D-configuration or in the L-, or both in the D- and L-configurations. The D-configuration is preferred. Each nucleoside residue independently can be in the alpha- or beta-configuration, but most preferably is in the beta-D-configuration. The furanosyl moieties can include ribofuranosyl, 2'-deoxyribofuranosyl, 3'-deoxyribofuranosyl, 2', 3'-dideoxyribofuranosyl, arabinofuranosyl, 3'-deoxyarabinofuranosyl, xylofuranosyl, 2'-
25 deoxyxylofuranosyl, and lyxofuranosyl derivatives, with the ribofuranosyl and the 2'-deoxyribofuranosyl moieties being preferred.

In the general structure of Formula III, the dotted lines are intended to indicate the presence of single or double bonds in these positions; the relative positions of the double or single bonds being determined by whether the R₁₀ and R₁₁ substituents are capable of
30 keto-enol tautomerism.

In the general structure of Formula IV, the dotted lines in the 2- to 4-positions are intended to indicate the presence of single or double bonds in these positions; the relative positions of the double or single bonds being determined by whether the R₁₄, R₁₅, and R₁₈

substituents are capable of keto-enol tautomerism. When R₁₄ is double-bonded from an oxygen or sulfur atom to the carbon at the 4-position of the pyrimidine ring, R₁₅ is hydrogen.

As used herein, the term "alkyl" refers to C₁₋₁₀ inclusive, linear, branched, or cyclic, saturated or unsaturated (i.e., alkenyl and alkynyl) hydrocarbon chains, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl, butadienyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, allenyl and optionally substituted arylalkenyl and arylalkynyl groups. As used herein, the term "acyl" refers to an organic acid group wherein the -OH of the carboxyl group has been replaced with another substituent (i.e., as represented by X'CO- or X'CS-, wherein X' is a hydrogen, an alkyl, an aralkyl, an aryl, an alkoxy, an aryloxy, an aralkoxy, an amino, N-substituted amino or an N,N-disubstituted amino group). As such, the term "acyl" specifically includes arylacyl groups. Specific examples of acyl groups include acetyl and benzoyl. As used herein, the term "aryl" refers to carbocyclic and heterocyclic aromatic groups of 5 to 12 ring atoms. Examples of aryl groups include phenyl, naphthyl, furan, thiophene, pyrrole, pyridine, imidazole, isothiazole, isoxazole, pyrazole, pyrazine, and the like. The term "alkoxy" as used herein refers to C₁₋₁₀ inclusive, linear, branched, or cyclic, saturated or unsaturated hydrocarbon chains bonded to an oxygen atom. This includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, and decyloxy. The term "aryloxy" as used herein refers to groups such as phenyloxy, as well as alkyl-, halo-, and/or alkoxy-substituted aryloxy groups. The term "thioalkyl" as used herein refers to C₁₋₁₀ inclusive, linear, branched, cyclic, saturated or unsaturated hydrocarbon chains bonded to a sulfur atom. This includes, for example, thiomethyl, thioethyl, thiopropyl, thioisopropyl, thiobutyl, thio-t-butyl, and thiodecyl. The term "thioaryl" as used herein refers to groups such as thiophenyl, as well as alkyl-, halo-, and/or alkoxy-substituted thioaryl groups. As used herein, the terms "substituted alkyl" and "substituted aryl" include alkyl and aryl groups, as defined herein, in which one or more atoms or functional groups of the aryl or alkyl group are replaced with another atom or functional group, such as halogen, aryl, alkyl, alkoxy, hydroxy, nitro, amino, alkylamino, dialkylamino, sulfate, and thioalkyl. The terms "halo," "halide," or "halogen" as used herein refer to fluoro, chloro, bromo, and iodo groups.

Compounds illustrative of those of Formula I include those disclosed in WO 99/09998; the reference is incorporated herein by reference. Formula I compounds, for example, include: P₁, P₄-diadenosinetetraphosphate (A₂P₄); uridine-5'-diphosphate

(UDP); uridine-5'-O-(2-thiodiphosphate) (UDP β S); 5-bromouridine-5'-triphosphate (5-BrUTP); 5-(1-phenylethynyl)-uridine-5'-triphosphate (5-(1-phenylethynyl)UTP); 5-methyluridine-5'-diphosphate (5-methylUDP); 4-hexylthiouridine-5'-triphosphate (4-hexylthioUTP); 4-thiouridine-5'-triphosphate (4-thioUTP); 2-methoxyuridine-5'-triphosphate (2-methoxyUTP); 4-(1-morpholino)uridine-5'-tetraphosphate (4-(1-morpholino))UP₄; 4-hexyloxyuridine-5'-diphosphate (4-hexyloxyUDP); 4-(N, N-dimethyl)cytidine-5'-triphosphate (N, N-dimethylCTP); 4-(N-hexyl)cytidine-5'-triphosphate (N-hexylCTP); P¹-(cytidine-5')-P⁴-(uridine-5'-)tetraphosphate (CP₄U); P¹-O-(methyl)-P⁴-(uridine-5'-)tetraphosphate (MeP₄U) and 4-(N-cyclopentyl)thymidine-5'-triphosphate (N-cyclopentylCTP).

Preferred compounds of Formula I include 5'-adenosine-triphosphate (ATP), 5'-uridine-triphosphate (UTP), uridine-5'-O-(3-thiotriphosphate) (UTP γ S) and P¹-(uridine-5')-P⁴-(uridine-5'-)tetraphosphate (U₂P₄). Particularly preferred compounds of Formula I include 5'-[4-(thiouridine)]-triphosphate (4-thioUTP) and P¹-(cytidine-5')-P⁴-(uridine-5'-)tetraphosphate (CP₄U). Certain compounds of Formula I (e.g., UTP, dUDP, ATP γ S, and 4-thioUDP) are known and can be made in accordance with known procedures or variations thereof, which will be apparent to those skilled in the art. For example, the identification and preparation of certain thiophosphate analogues of nucleoside diphosphates (such as UDP- β -S) are set forth in U.S. Patent No. 3,846,402 and Goody and Eckstein (*J. Am. Chem. Soc.* 93: 6252-6257 (1971)). Alternatively, UTP, and other analogs thereof are also commercially available from vendors such as Sigma (St. Louis, MO) and Pharmacia (Uppsala, Sweden).

One embodiment of the present invention is a method of using a hydrolysis-resistant agonist. A hydrolysis-resistant agonist is a nucleotide with a modified phosphate ester backbone, e.g. a methylene, imido or other group, or some other structural modification that protects the phosphate ester and/or phosphate anhydride bonds from being readily hydrolyzed. Another embodiment is a method of using a dinucleoside polyphosphate, which is also resistant to hydrolysis due to a lack of a terminal phosphate group. Certain dinucleoside polyphosphates are especially resistant to hydrolysis. For example, P¹-(cytidine-5')-P⁴-(uridine-5'-)tetraphosphate is more resistant in comparison with P¹, P⁴-Di(uridine-5'-)tetraphosphate. Furthermore, groups placed on the end of the phosphate chain impart some stability against hydrolysis, e.g. simple alkyl phosphate esters (methyl, ethyl, benzyl, etc.) or thiophosphate derivatives (e.g. UTP γ S) hydrolyze

more slowly. Many P2Y agonists are dinucleotides or dinucleotide analogues, and many of these are particularly active at P2Y₂ receptors. Dinucleoside polyphosphates of general Formula I are useful in this application. Thus, yet another preferred embodiment of the present invention is a method of stimulating secretions in an affected joint using P2Y₂ receptor agonists.

Compounds encompassed by the present invention can be prepared by condensation of a nucleoside mono-, di-, or triphosphate, activated with a condensing agent such as, but not limited to, carbonyldiimidazole or dicyclohexylcarbodiimide, with a second molecule of the same or a different mono-, di-, or triphosphate to form the desired dinucleoside polyphosphate. Another method of preparation is the sequential condensation of a nucleoside phosphate, activated as above, with a non-nucleoside mono-, di- or polyphosphate moiety such as, but not limited to, a monophosphate or pyrophosphate anion to yield the desired dinucleoside polyphosphate, the non-isolated intermediate in such a case being a mononucleoside polyphosphate. Yet another preparative approach is the sequential condensation of a mono-, di- or polyphosphate moiety, activated as mentioned above, or in the form of an acid halide or other derivative reactive toward nucleophilic displacement, with a nucleoside phosphate or polyphosphate to yield the desired dinucleoside polyphosphate. The desired dinucleoside polyphosphate can be formed by modification of a pre-formed dinucleoside polyphosphate by substitution or derivatization of a moiety or moieties on the purine, pyrimidine or carbohydrate rings. Nucleoside phosphates used as starting materials may be commercially available, or they can be made from the corresponding nucleosides by methods well known to those skilled in the art. Likewise, where nucleosides are not commercially available, they can be made by modification of other readily available nucleosides, or by synthesis from heterocyclic and carbohydrate precursors by methods well known to those skilled in the art.

Those having skill in the art will recognize that the starting materials can be varied and additional steps employed to produce compounds encompassed by the present invention. In some cases protection of certain reactive functionalities may be necessary to achieve some of the above transformations. In general, the need for such protecting groups will be apparent to those skilled in the art of organic synthesis as well as the conditions necessary to attach and remove such groups.

The compounds of the present invention also encompass their non-toxic pharmaceutically acceptable salts, such as, but not limited to, an alkali metal salt such as

lithium, sodium or potassium; an alkaline earth metal salt such as magnesium or calcium; or an ammonium or tetraalkyl ammonium salt, i.e., NL_4^+ (wherein L is C_{1-4}), with the monovalent salts such as lithium, sodium, potassium, and ammonium being most preferred. Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects. The present invention also encompasses the acylated prodrugs of the compounds disclosed herein. Those skilled in the art will recognize various synthetic methodologies which can be employed to prepare non-toxic pharmaceutically acceptable salts and acylated prodrugs of the compounds (International Patent Nos. WO 96/40059, WO 96/02554A1, WO-A-9815563, and WO 98/55494; Theoclitou, *et al.*, *J. Chem. Soc. Perkin Trans. I*, 2009-2019 (1996); Guranowski, *et al.*, *Nucleosides and Nucleotides* 14, 731-734 (1995); Visscher, *et al.*, *Nucleic Acids Research* 20, 5749-5752 (1992); Holler, *et al.*, *Biochemistry* 22, 4924-4933 (1983); Orr, *et al.*, *Biochem. Pharmacol.* 673-677 (1988); Plateau, *et al.*, *Biochemistry* 24, 914-922 (1985); Hagmeier, *et al.*, *J. Chromatography* 237, 174-177 (1982); Scheffzek, *et al.*, *Biochemistry* 35, 9716-9727 (1996); Stridh, *et al.*, *Antiviral Res.*, 97-105 (1981); Tarasova, *et al.*, *Chem. Abs.* 110, 154770 (1988); Hata, *et al.*, *Chem Lett.*, 987-990 (1976); Huhn, *et al.*, 28, 1959-1970 (1993); Tumanov, *et al.*, *Chem. Abs.* 109-6867d (1987); Pintor, *et al.*, *Molecular Pharmacology* 51, 277-284 (1997); and U.S. Patent Nos. 4,855,304; 5,635,160; 5,495,550; and 5,681,823).

The pharmaceutical utility of compounds of this invention is indicated by the cytosolic calcium assay for $P2Y_2$ and other $P2Y$ receptor activity. This widely used assay, as described in Pendergast, *et al.* (2001) (*Bioorg. Med. Chem. Lett.* 11, 157-160), relies on the measurement of increased cytosolic calcium levels to determine the biological activity of compounds that activate receptors linked via G-proteins to phospholipase C. The efficacy of these compounds is reflected in their ability to alter and/or enhance the secretory activity of the joints, including but not limited to, the knee, hip, and shoulder, to effectuate the agent's target response. The target response is the improvement of joint lubrication and movement.

Dosage levels of the order of from about 10^{-7} M to about 10^{-1} M, preferably in the range 10^{-5} to 10^{-1} M, are useful in the treatment of the above-indicated conditions, including disorders of joint lubrication. The effective dose ranges between about 0.1 to about 1000 mg, preferably between about 0.1 to about 100 mg, and most preferably between about 0.5 to about 50 mg for single doses. The amount of active ingredients that can be combined with the carrier materials to produce a single dosage form will vary

depending upon the host treated and the particular mode of administration. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of
5 administration, and rate of excretion, drug combination and the severity of the particular disease in the patient undergoing therapy, and can be determined by those skilled in the art.

Though the compounds of the present invention are primarily concerned with the treatment of human subjects, they can also be employed for the treatment of other
10 mammalian subjects such as dogs, cats and horses for veterinary purposes.

The compounds disclosed herein can be administered to the joint of a patient by any suitable means, such as by topical, intra-articular injection or systemic administration. Topical administration includes the use of a solution, gel, suspension, cream, or ointment containing the active compound in a physiologically compatible vehicle. Gels or jellies
15 can be produced using a suitable gelling agent including, but not limited to, gelatin, tragacanth, or a cellulose derivative and can include glycerol as a humectant, emollient, and preservative. Ointments are semi-solid preparations that consist of the active ingredient incorporated into a fatty, waxy, or synthetic base. Examples of suitable creams include, but are not limited to, water-in-oil and oil-in-water emulsions. Water-in-oil
20 creams can be formulated by using a suitable emulsifying agent with properties similar to emulsifying wax, or similar to those of the fatty alcohols, such as cetyl alcohol or cetostearyl alcohol. Oil-in-water creams can be formulated using an emulsifying agent such as cetomacrogol emulsifying wax. Suitable properties include the ability to modify the viscosity of the emulsion and both physical and chemical stability over a wide range
25 of pH. The water soluble or miscible cream base can contain a preservative system and can also be buffered to maintain an acceptable physiological pH.

Alternatively, the active compounds can be administered by a continuous release device. Those skilled in the art of delivery system development can select using conventional criteria. Solutions formulated for administration to the joint are usually
30 referred to as irrigations. These are sterile solutions, prepared in a manner typical of sterile injections that are intended as a single use sterile solution.

Foam preparations can be formulated to be delivered from a pressurized aerosol canister, via a suitable applicator, using inert propellants. Suitable excipients for the formulation of the foam base include, but are not limited to, propylene glycol,

emulsifying wax, cetyl alcohol, and glyceryl stearate. Potential preservatives include methylparaben and propylparaben.

Another method of topical administration is by delivery through the vagina. Pessaries are solid unit-dose forms suitably shaped for insertion into the vagina and can either be composed of a base that melts at body temperature or which dissolves when in contact with mucous secretions. Examples of suitable bases include, but are not limited to, theobroma oil, synthetic fat bases (e.g. Witepsol), polyethylene glycols (macrogols), and glycerol suppository bases. Vaginal tablets are composed of the active ingredient contained within a solid dosage form base which can include, but not be limited to, excipients such as lactose, microcrystalline cellulose, corn starch, magnesium stearate, silicon dioxide, and hydroxypropyl methylcellulose.

Another means of administration of the active compound to the synovial tissues of the subject involves intra-articular injection of the active compound, such that a therapeutically effective amount of the compound reaches the synovial tissues locally.

A further means of administration of the active compounds is systemically via various methods. One such means involves an aerosol suspension of respirable particles comprised of the active compound, which the subject inhales. The active compound is absorbed into the bloodstream via the lungs and contacts the synovial tissues in a pharmaceutically effective amount. The respirable particles can be liquid or solid, with a particle size sufficiently small to pass through the mouth and larynx upon inhalation; in general, particles ranging from about 1 to 10 microns, but more preferably 1-5 microns in size are considered respirable.

Another means of systemically administering the active compounds to the synovial tissues of the subject involve administering a liquid/liquid suspension in the form of nasal drops of a liquid formulation, or a nasal spray of respirable particles that the subject inhales. Liquid pharmaceutical compositions of the active compound for producing a nasal spray or nasal drops are prepared by combining the active compound with a suitable vehicle, such as sterile pyrogen free water or sterile saline by techniques known to those skilled in the art.

Other means of systemic administration of the active compound involve oral administration, in which pharmaceutical compositions containing a compound or compounds of Formula I are in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use can be prepared according to any method known to

the art; such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents, and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets can be prepared to contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients can be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrating agents, for example, corn starch or alginic acid; binding agents, for example, starch, gelatin, or acacia; and lubricating agents, for example magnesium stearate, stearic acid, or talc. The tablets can be uncoated or they can be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate, or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil.

The active compounds can also be delivered to a subject through absorption by the skin using transdermal patches or pads. The active compounds are absorbed into the bloodstream through the skin. Plasma concentrations of the active compounds can be controlled using patches containing different levels of active compounds.

Additional means of systemic administration of the active compound to the synovial tissues of the subject involve a suppository form of the active compound, such that a therapeutically effective amount of the compound reaches the synovial tissues via systemic absorption and circulation.

The invention is illustrated further by the following examples of treatment, which are not to be construed as limiting the scope or spirit to the specific procedures described in them.

30

Example 1

Measurement of cytosolic calcium in cultured synovial fibroblasts.

A conventional technique was used to detect increases in cytosolic calcium induced by P2Y receptor agonists, a technique familiar to those skilled in the art. Cells were seeded in 96-well plates and used for cytosolic calcium assays. On the day of the

assay, the growth medium was aspirated and replaced with a solution of Fluo-3 AM (2.5 μ M final concentration) in an assay buffer consisting of (mM): KCl (10), NaCl (118), CaCl₂ (2.5), MgCl₂ (1), HEPES (20), glucose (10), pH 7.4. Probenecid (Sigma Chemical Co.) was added to the dye load and dye wash medium at a working concentration of 2.5 mM to increase dye retention in the cells. After a 60 minute incubation with Fluo-3 AM at 25°C, cells were washed free of dye (Columbus Plate Washer, TECAN U.S., Inc., Research Triangle Park, N.C.) and were stimulated with increasing concentrations of P2Y receptor agonists. Intracellular calcium levels were simultaneously monitored in each well by measuring the changes in fluorescence intensity using the FLIPR (Molecular Devices Corp., Sunnyvale, CA).

Synovial fibroblasts were subjected to the cytosolic calcium assay described above. The results show that the P2Y receptor agonists ATP and UTP stimulate increases in cytosolic calcium in these cells, consistent with activation of the P2Y₂ receptors in synoviocytes (Figure 1). 2-methylthioADP, a P2Y₁ receptor-selective agonist, did not alter cytosolic calcium concentration in synovial fibroblasts, indicating the lack of P2Y₁ receptors in these cells. The induction of increases in cytosolic calcium by ATP and UTP in synovial fibroblasts indicated the pharmaceutical utility of P2Y₂ receptor agonists in the joint.

Example 2

Effects of Purinergic Receptor Agonist in Patients with Osteoarthritis

A formulation of a pharmaceutical composition that is a purinergic receptor agonist of Formula I, together with a pharmaceutically acceptable carrier, is prepared as a sterile solution for administration by intra-articular injection. This formulation is administered to patients to achieve a joint fluid concentration in the range of 10⁻⁷ M to 10⁻¹ M. Patients demonstrating typical clinical manifestations of osteoarthritis are diagnosis and selected for treatment on the basis of pattern of joint involvement, radiographic features, laboratory tests, and synovial fluid findings. At baseline and after treatment with the formulation, the patients undergo examinations including history, physical examinations by specialists, routine laboratory studies, radiographic assessment, and analysis of joint fluid.

Criteria for Therapeutic Efficacy

One of the criteria for determining the effectiveness of treatment with the formulation is the normalization of at least one joint fluid characteristic, including but not

limited to synovial fluid coloration, viscosity and a WBC count of less than 2,000/ μ L. In patients with synovitis, normalization of erythrocyte sedimentation rate is another criteria for determining the effectiveness of treatment. Alternative criteria are the improvement of joint movement, including a decrease in joint stiffness, less restriction of joint rotation, and/or a reduction in crepitation, improvement in radiographic (x-ray) findings including reduction of joint space narrowing, subchondral bone sclerosis, subchondral cysts, and osteophytes, and a reduction in joint pain. The formulation improves at least one of the above symptoms or criteria.

10 The invention and the manner and process of making and using it are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the present invention and that modifications can be made therein without departing from the spirit or scope of the present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

WHAT IS CLAIMED IS:

1. A method of altering the amount or composition of synovial fluids secreted from joints in a subject in need of such treatment comprising:

5 administering to a subject a purinergic receptor agonist in an amount therapeutically effective to alter the amount or composition of synovial fluids.


2. A method according to Claim 1, wherein said purinergic receptor agonist is administered in an amount therapeutically effective to affect a response selected from
10 the group consisting of: enhancing joint lubrication, treating osteoarthritis, and stimulating secretions of synovial fluids, lubricin, hyaluronic acid, or surface-active phospholipid.

3. The method according to Claim 1 wherein said purinergic receptor agonist
15 is a P2Y purinergic receptor agonist.

4. The method according to Claim 3, wherein said P2Y purinergic receptor agonist is a nucleoside polyphosphate of Formula I:

Formula I

20



wherein:

25 X_1 , X_2 , and X_3 are independently or together oxygen, methylene, monochloromethylene, dichloromethylene, monofluoromethylene, difluoromethylene, or imido;

T , T' , W , and V are independently or together oxygen or sulfur;

$m = 0, 1$ or 2 ;

$n = 0$ or 1 ;

$p = 0, 1$, or 2 ;


where the sum of $m+n+p$ is from 1 to 5;

each M is independently hydrogen or a pharmaceutically-acceptable inorganic or organic counterion;

A = M, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aralkenyl, aralkynyl,

5 aryl, or acylthioalkyl, with or without substituents or heteroatoms; or

A is a nucleoside residue defined as:



10 wherein:

D_1 and D_2 are each independently O or C.


Z and Z' are independently H, OR_2 or OR_3 ;

Y and Y' are independently H, F, OR_1 or OR_4 ;

independently R_1 , R_2 , R_3 , and R_4 is H, or a residue according to Formula II, provided that

15 at least one R_1 , R_2 , R_3 , or R_4 is H;

Formula II



20 wherein:

Q is a carbon atom;

R_5 , R_6 , and R_7 are independently H, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aralkenyl, aralkynyl, aryl, or heterocyclic moiety, or


R_5 and R_6 are taken together to form a carbocyclic or heterocyclic ring of 4 to 7 members,

25 such that the moiety defined according to Formula II is an ether; or


provided that R_5 and R_6 are taken together as oxygen or sulfur doubly bonded to Q, and

R_7 is substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aralkenyl, aralkynyl, or a heterocycle of 4 to 7 members, such that the moiety defined according to Formula II is an ester or thioester; or

- provided that R_5 and R_6 are taken together as oxygen or sulfur doubly bonded to Q, and R_7 is amino or mono- or disubstituted amino, where the substituents are alkyl, cycloalkyl, aralkyl, aryl, substituted aralkyl, or substituted aryl, or where the substituents on nitrogen form a heterocyclic ring of 4 to 7 members such that the moiety according to Formula II
- 5 is a carbamate or thiocarbamate; or
- provided that R_5 and R_6 are taken together as oxygen or sulfur doubly bonded to Q, and R_7 is alkoxy, cycloalkoxy, aralkyloxy, aryloxy, substituted aralkyloxy, or substituted aryloxy, such that the moiety according to Formula II is a carbonate or thiocarbonate;
- B and B' are independently a purine or a pyrimidine residue according to Formulae III or
- 10 IV which is linked to the 1'-position of the furanose or carbocycle via the 9-position of the purine or the 1- position of the pyrimidine;

Formula III


15

Formula IV

wherein:

- R₁₀ and R₁₄ are independently CN, N₃, hydroxy, oxo, amino, mercapto, alkylthio, alkoxy, aryloxy, alkylamino, cycloalkylamino, aralkylamino, arylamino, diaralkylamino, diarylamino, N-alkyl-N-aryl amino, or dialkylamino, where the alkyl and/or aryl groups are optionally linked to form a heterocycle; or
- R₁₀ and R₁₄ are independently acylamino, according to Formula V; or

Formula V



10

- when R₁₀ or R₁₄ has as its first atom nitrogen, R₁₀ and R₁₁ or R₁₄ and R₁₅ are taken together as -CH=CH- to form a 5-membered, fused imidazole ring, optionally substituted on the imidazole ring with substituted- or unsubstituted- alkyl, cycloalkyl, aralkyl, or aryl moieties;

15

J is carbon or nitrogen, with the provision that when J is nitrogen, R₁₂ is not present;

R₁₁ is hydrogen, O, or is absent;

- R₁₂, when present, is hydrogen, alkyl, azido, amino, alkylamino, arylamino, aralkylamino, dialkylamino, diarylamino, diaralkylamino, N-alkyl-N-aryl amino, N-alkyl-N-aralkylamino, N-aralkyl-N-aryl amino, hydroxy, alkoxy, aryloxy or aralkyloxy, sulfhydryl, alkylthio, arylthio or aralkylthio, or ω-X(C₁₋₆alkyl)G- wherein X is substituted- or unsubstituted- amino, mercapto, hydroxy or carboxyl, and G is -O-, -S-, -NR₂₀-, -N(CO)R₂₀-, or N(CO)OR₂₂;

20

- R₁₃ is hydrogen, chlorine, fluorine, hydroxy, alkoxy, aryloxy, aralkyloxy, amino, monosubstituted amino, disubstituted amino, alkylthio, trifluoroalkylthio, arylthio, or aralkylthio, where the substituent on sulfur contains up to a maximum of 20 carbon atoms, with or without unsaturation;

25

R₁₅ is hydrogen, or acyl with or without substituents;

- R₁₆ is hydrogen, methyl, substituted- or unsubstituted-alkyl, halo, aryl, aralkyl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl;

30

- R₁₇ is halogen, hydrogen, alkoxy or is an acylamino group according to Formula V; or R₁₆ and R₁₇, when taken together, represent a ring of 5 to 7 members, with or without heteroatoms or substituents;
- R₁₈ is hydrogen, oxo, alkoxy, amino, alkylamino, arylamino, aralkylamino, dialkylamino, diarylamino, arylalkylamino, arylaralkylamino, alkylaralkylamino, sulfhydryl, alkylthio, arylthio, aralkylthio, or acylamino according to Formula V;
- R₁₉ is amino or mono- or disubstituted amino such that the moiety according to Formula V is a urea or thiourea; or
- R₁₉ is alkoxy, aralkyloxy or aryloxy, such that the moiety according to Formula V is a carbamate or thiocarbamate; or
- R₁₉ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, aralkenyl, aralkynyl, with or without substituents or heteroatoms, such that the moiety according to Formula V is an amide or thioamide;
- R₂₀ and R₂₁ independently are hydrogen, alkyl, cycloalkyl, aralkyl, or aryl, with or without substituents or heteroatoms;
- R₂₂ is alkyl, cycloalkyl, aralkyl, or aryl, with or without substituents or heteroatoms; and W₁ is oxygen or sulfur.

5. The method according to Claim 4, wherein at least one of the sugar moieties of said nucleoside polyphosphate is selected from the group consisting of: ribofuranosyl, 2'-deoxyribofuranosyl, 3'-deoxyfuranosyl, 2',3'-dideoxyribofuranosyl, arabinofuranosyl, 3'-deoxyarabinofuranosyl, xylofuranosyl, 2'-deoxyxylofuranosyl and lyxofuranosyl.

6. The method according to Claim 4, wherein said nucleoside polyphosphate is selected from the group consisting of nucleoside diphosphates, nucleoside triphosphates, and dinucleoside polyphosphates.

7. The method according to Claim 6, wherein said nucleoside polyphosphate is selected from the group consisting of uridine-5'-diphosphate, adenosine-5'-diphosphate, cytidine-5'-diphosphate, uridine-5'-triphosphate, adenosine-5'-triphosphate, cytidine-5'-triphosphate, and ethenocytidine-5'-triphosphate.

8. The method according to Claim 6, wherein said dinucleoside polyphosphates of general Formula I are dinucleoside tetraphosphates selected from the group consisting of P^1, P^4 -di(uridine-5'-)tetraphosphate; P^1 -(cytidine-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1, P^4 -di(adenosine-5'-)tetraphosphate; P^1 -(adenosine-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1 -(adenosine-5'-) P^4 -(cytidine-5'-)tetraphosphate; P^1, P^4 -di(ethenoadenosine)tetraphosphate; P^1 -(uridine-5'-) P^4 -(thymidine-5'-)tetraphosphate; P^1 -(adenosine-5'-) P^4 -(inosine-5'-)tetraphosphate; P^1, P^4 -di(uridine-5'-) P^2, P^3 -methylenetetraphosphate; P^1, P^4 -di(uridine-5'-) P^2, P^3 -difluoromethylenetetraphosphate; P^1, P^4 -di(uridine-5'-) P^2, P^3 -imidotetraphosphate; P^1, P^4 -di(4-thiouridine-5'-)tetraphosphate; P^1, P^4 -di(3,N⁴-ethenocytidine-5'-)tetraphosphate; P^1, P^4 -di(imidazo[1,2-c]pyrimidine-5(6H)-one-2-(3-nitrophenyl)-6-β-D-ribofuranoside-5'-)tetraphosphate; P^1 -(inosine-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1 -(4-thiouridine-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1 -(cytosine-β-D-arabinofuranoside-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1 -(uridine-5'-) P^4 -(xanthosine-5'-)tetraphosphate; P^1 -(2'-deoxyuridine-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1 -(3'-azido-3'-deoxythymidine-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1, P^4 -di(3'-azido-3'-deoxythymidine-5'-)tetraphosphate; P^1, P^4 -di(3'-azido-3'-deoxythymidine-5'-)tetraphosphate; 2'(3')-benzoyl- P^1, P^4 -di(uridine-5'-)tetraphosphate; P^1, P^4 -di(2'(3')-benzoyluridine-5'-)tetraphosphate; P^1 -(2'-deoxyguanosine-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1 -(2'-deoxyadenosine-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1 -(2'-deoxyinosine-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1 -(2'-deoxycytidine-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1 -(8-azaadenosine-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1 -(6-mercaptopurineriboside-5'-) P^4 -(uridine-5'-)tetraphosphate; P^1 -(6-mercaptopurineriboside-5'-) P^4 -(2'-deoxyuridine-5'-)tetraphosphate; P^1 -(4-thiouridine-5'-) P^4 -(arabinocytidine-5'-)tetraphosphate; P^1 -(adenosine-5'-) P^4 -(4-thiomethyluridine-5'-)tetraphosphate; P^1 -(2'-deoxyadenosine-5'-) P^4 -(6-thiohexylpurineriboside-5'-)tetraphosphate and P^1 -(6-decyloxypurineriboside-5'-) P^4 -(uridine-5'-)tetraphosphate.

9. The method according to Claim 6, wherein said dinucleoside polyphosphates of general Formula I are dinucleoside triphosphates selected from a group consisting of: P^1, P^3 -di(uridine-5'-)triphosphate; P^1 -(cytidine-5'-) P^3 -(uridine-5'-)triphosphate; P^1, P^3 -di(adenosine-5'-)triphosphate; P^1 -(adenosine-5'-) P^3 -(uridine-5'-)triphosphate; P^1 -(adenosine-5'-) P^3 -(cytidine-5'-)triphosphate; P^1, P^3 -

di(ethenoadenosine)triphosphate; P^1 -(uridine-5'-) P^3 -(thymidine-5'-)triphosphate; P^1 -(adenosine-5'-) P^3 -(inosine-5'-)triphosphate; P^1, P^3 -di(uridine-5'-) P^2, P^3 -methylenetriphosphate; P^1, P^3 -di(uridine-5'-) P^2, P^3 -difluoromethylenetriphosphate; P^1, P^3 -di(uridine-5'-) P^2, P^3 -imidotriphosphate; P^1, P^3 -di(4-thiouridine-5'-)triphosphate;

5 P^1, P^3 -di(3,N⁴-ethenocytidine-5'-)triphosphate; P^1, P^3 -di(imidazo[1,2-c]pyrimidine-5(6H)-one-2-(3-nitro)-phenyl-6-β-D-ribofuranoside-5'-)triphosphate; P^1 -(inosine-5'-) P^3 -(uridine-5'-)triphosphate; P^1 -(4-thiouridine-5'-) P^3 -(uridine-5'-)triphosphate; P^1 -(cytidine-β-D-arabinofuranoside-5'-) P^3 -(uridine-5'-)triphosphate; P^1 -(uridine-5'-) P^3 -(xanthosine-5'-)triphosphate; P^1 -(2'-deoxyuridine-5'-) P^3 -(uridine-5'-)triphosphate; P^1 -(3'-azido-3'-deoxythymidine-5'-) P^3 -(uridine-5'-)triphosphate; P^1, P^3 -di(3'-azido-3'-deoxythymidine-5'-)triphosphate; 2'(3')-benzoyl- P^1, P^3 -di(uridine-5'-)triphosphate; P^1, P^3 -Di(2'(3')-benzoyluridine-5'-)triphosphate; P^1 -(2'-deoxyguanosine-5'-) P^3 -(uridine-5'-)triphosphate; P^1 -(2'-deoxyadenosine-5'-) P^3 -(uridine-5'-)triphosphate; P^1 -(2'-deoxyinosine-5'-) P^3 -(uridine-5'-)triphosphate; P^1 -(2'-deoxycytidine-5'-) P^3 -(uridine-5'-)triphosphate;

15 triphosphate; P^1 -(4-thiouridine-5'-) P^3 -(uridine-5'-)triphosphate; P^1 -(8-azaadenosine-5'-) P^3 -(uridine-5'-)triphosphate; P^1 -(6-mercaptopurineriboside-5'-) P^3 -(uridine-5'-)triphosphate; P^1 -(6-mercaptopurineriboside-5'-) P^3 -(2'-deoxyuridine-5'-)triphosphate; P^1 -(4-thiouridine-5'-) P^3 -(arabinocytidine-5'-)triphosphate; P^1 -(adenosine-5'-) P^3 -(4-thiomethyluridine-5'-)triphosphate; P^1 -(2'-deoxyadenosine-5'-) P^3 -(6-thiohexylpurine riboside-5'-)triphosphate; and P^1 -(6-nonyloxypurineriboside-5'-) P^3 -(uridine-5'-)triphosphate.

10. The method according to Claim 6, wherein said dinucleoside polyphosphates of general Formula I are selected from a group consisting of: P^1 -(uridine-5'-) P^2 -(4-thiouridine-5'-)diphosphate; P^1, P^5 -di(uridine-5'-)pentaphosphate; and P^1, P^6 -di(uridine-5'-)hexaphosphate.

25

11. The method according to Claim 4, wherein said nucleoside polyphosphate is in a sterile formulation of a pharmaceutical composition, further comprising a

30 pharmaceutically suitable carrier therefor.

12. The method according to Claim 11, wherein said pharmaceutical composition comprising said nucleoside polyphosphate is administered to achieve a joint fluid concentration range of about 10^{-7} M to about 10^{-1} M.

5 13. The method according to Claim 12, wherein said pharmaceutical composition comprising said P2Y purinergic receptor agonist is administered to achieve a joint fluid concentration range of about 10^{-5} to 10^{-1} M.

10 14. The method according to Claim 4, wherein said nucleoside polyphosphate is co-administered with an existing therapeutic agent for managing arthritis.

15 15. The method according to Claim 14, wherein said existing therapeutic agent is selected from the group consisting of an analgesic agent, anti-inflammatory agent, muscle relaxant, anti-depressant, and an agent that promotes joint lubrication.

16. The method according to Claim 1, wherein said administering is topical administration of said compound.

20 17. The method according to Claim 16, wherein said compound is administered in a form of a solution, a gel, a suspension, a cream, an ointment, a foam, a pessary or a tablet.

25 18. The method according to Claim 1, wherein said administering is systemic or local administration of said compound.

19. The method according to Claim 18, wherein said systemic administration is administered to said subject with said compound in a form selected from the group consisting of: an aerosol suspension of respirable particles; a liquid or liquid suspension for administration as nose drops or nasal spray; a nebulized liquid for administration to oral or nasopharyngeal airways; an oral form; a suppository form; an injectable form; and a transdermal patch or a transdermal pad; such that a therapeutically effective amount of said compound contacts the synovial tissues of said subject via systemic absorption and circulation.

20. The method according to Claim 19, wherein said local administration is administered to said subject with said compound an injectable form for local intra-articular administration to the affected joint.

1/1




FIGURE 1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/20703

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01N 43/04
 US CL : 514/51,49,50,885

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 514/51,49,50,885; 536/28.53

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GREEN et al. Purinergic regulation of bradykinin-induced plasma extravasation and adjuvant-induced arthritis in the rat. Proc. Natl. Acad. Sci. May 1991, Vol. 88, No. 10, pages 4162-5, especially page 4165.	1-7, 11, 17-20
---		-----
Y		8-10, 12-16
Y	US 5,837,861 A (PENDERGAST ET AL) 17 November 1998 (17.11.1998), column 1, line 5 through column 5, line 45.	8-10, 12-16
A	US 5,985,849 A (KINDON ET AL) 16 November 1999 (16.11.1999), column 1, line 4 through column 3, line 67.	1-20
A	US 5,415,873 A (TREPEL ET AL) 16 May 1995 (16.05.1995), abstract and column 1, line 10 through column 4, line 42.	1-20
A	US 6,323,187 B1 (YERXA ET AL) 27 November 2001 (27.11.2001), column 1, line 10 through column 3, line 50.	1-20



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 September 2002 (25.09.2002)

Date of mailing of the international search report

05 NOV 2002

Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Sreeni Padmanabhan

Telephone No. (703) 308-1234

INTERNATIONAL SEARCH REPORT

PCT/US02/20703

Continuation of B. FIELDS SEARCHED Item 3:

WEST: all files, terms: purinergic, receptro, agonist, inflammation, synovial, arthritis, osteoarthritis, nucleoside, joint.

CAS ONLINE: files-CAPLUS, terms-synovial, arthrities, osteoarthritis, purinergic, P2Y, agonist, ATP